Innoviva reported Q2 2026 revenue of $119.6 million, increasing 19% year-over-year, driven by its royalty portfolio and net product sales growth from its IST platform. The company also launched Nortiva Bio and announced a licensing agreement with Dr. Reddy's Laboratories.